Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

PHASE2TerminatedINTERVENTIONAL
Enrollment

299

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

February 28, 2005

Conditions
Rheumatoid Arthritis
Interventions
DRUG

natalizumab

DRUG

placebo

Trial Locations (12)

16635

Altoona Center for Clinical Research, Duncansville

19090

Rheumatic Disease Associates, Willow Grove

32216

Jacksonville Center for Clinical Research, Jacksonville

35294

University of Alabama at Birmingham, Birmingham

48910

Justus Fiechtner, MD, PC, Lansing

75235

Radiant Research, Dallas

85719

Clinical Research Unit / University of Arizona, Tucson

92025-4402

Arthritis Medical Clinic of North County, Inc., Escondido

02114

Massachusetts General Hospital, Boston

01610

Clinical Pharmacology Study Group, Worcester

A1C 5B8

St. Clare's Mercy Hospital, St. John's

L3Y 3R7

The Arthritis Program Research Group Inc., Newmarket

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Elan Pharmaceuticals

INDUSTRY

lead

Biogen

INDUSTRY

NCT00083759 - Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate | Biotech Hunter | Biotech Hunter